NewCo News: RGo Taps MedChem Expertise to Tackle RNAi Delivery Challenges Oct. 23, 2008 By Trista Morrison
Adventrx Restructures to Focus Efforts on ANX-530 and ANX-514 Oct. 21, 2008 By Trista Morrison A year after lead product CoFactor (ANX-510) failed a Phase IIb trial, Adventrx Pharmaceuticals Inc. is restructuring to focus on its chemotherapy emulsion products, ANX-530 and ANX-514. (BioWorld Today)Read More
